Enanta Pharmaceuticals, Inc (ENTA)

Etorro trading 970x250
Enanta Pharmaceuticals, Inc (ENTA) Logo

About Enanta Pharmaceuticals, Inc

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts. Address: 500 Arsenal Street, Watertown, MA, United States, 02472

Enanta Pharmaceuticals, Inc News and around…

Latest news about Enanta Pharmaceuticals, Inc (ENTA) common stock and company :

What 7 Analyst Ratings Have To Say About Enanta Pharmaceuticals
20 Oct, 2021 FinancialContent

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

Enanta Plans To Start Human Trials For Its COVID-19 Candidate In 2022
19 Oct, 2021 FinancialContent

Enanta Pharmaceuticals Inc(NASDAQ: ENTA) hasreported new preclinical datafor EDP-235, its recently announced lead ...

Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021
19 Oct, 2021 FinancialContent

Enanta Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference

Senior VP And Chief Medical Officer Of Enanta Pharmaceuticals Trades $2.0M In Company Stock
14 Oct, 2021 Yahoo! Finance

Nathalie Adda, Senior VP And Chief Medical Officer at Enanta Pharmaceuticals (NASDAQ:ENTA), made a large buy and sell of company shares on October 11, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Nathalie Adda exercised options to purchase 17,500 Enanta Pharmaceuticals shares at a price of $43.46 per share for a total of $760,550 on October 11. They then sold their shares on multiple transactions in the open market. Th

The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
12 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Enanta Pharmaceuticals (ENTA) Moves 10.6% Higher: Will This Strength Last?
08 Oct, 2021 Yahoo! Finance

Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Where Enanta Pharmaceuticals Stands With Analysts
07 Oct, 2021 FinancialContent

Analysts have provided the following ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) within the last quarter: ...

Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
07 Oct, 2021 FinancialContent

Upgrades For State Street Corporation (NYSE:STT), Wolfe Research upgraded the previous rating of Peer Perform to ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RS
06 Oct, 2021 FinancialContent

New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference

New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment
06 Oct, 2021 Yahoo! Finance

WATERTOWN, Mass., October 06, 2021--New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference

Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference
05 Oct, 2021 FinancialContent

Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference

Enanta To Discontinue Internal Development Of NASH Candidates
04 Oct, 2021 FinancialContent

After looking at interim phase 2b data,Enanta Pharmaceuticals Inc(NASDAQ: ENTA) hasdecided to stop the monotherapy ...

Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs
04 Oct, 2021 FinancialContent

Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs

Enanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021
01 Oct, 2021 FinancialContent

Enanta Pharmaceuticals Announces Data Presentations at AASLD’s The Liver Meeting® 2021

CORRECTED-FOCUS-COVID-19 pill developers aim to top Merck, Pfizer efforts
28 Sep, 2021 Yahoo! Finance

As Merck & Co and Pfizer Inc prepare to report clinical trial results for experimental COVID-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own. Enanta Pharmaceuticals, Pardes Biosciences, Japan's Shionogi & Co Ltd and Novartis AG said they have designed antivirals that specifically target the coronavirus while aiming to avoid potential shortcomings such as the need for multiple pills per day or known safety issues. Infectious disease experts stressed that preventing COVID-19 through wide use of vaccines remains the best way to control the pandemic.

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
09 Sep, 2021 FinancialContent

Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE:BLD) was changed from Hold to Buy. In the ...

How The Parts Add Up: VIOG Headed For $262
09 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard S&P Small-Cap 600 Growth ETF (VIOG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $261.96 per unit.

Enanta Pharmaceuticals to Participate in Investor Conferences in September
07 Sep, 2021 FinancialContent

Enanta Pharmaceuticals to Participate in Two Investor Conferences in September

The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
03 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
02 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
01 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
31 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors
23 Aug, 2021 FinancialContent

Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer
16 Aug, 2021 FinancialContent

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, its Oral Hepatitis B Virus RNA Destabilizer

Those who invested in Enanta Pharmaceuticals (NASDAQ:ENTA) five years ago are up 97%
13 Aug, 2021 Yahoo! Finance

While Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders are probably generally happy, the stock hasn't had...

Look Under The Hood: PSCH Has 18% Upside
09 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P SmallCap Health Care ETF (PSCH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $225.26 per unit.

Enanta Pharmaceuticals, inc (ENTA) Q3 2021 Earnings Call Transcript
06 Aug, 2021 FinancialContent

ENTA earnings call for the period ending June 30, 2021.

Enanta Pharmaceuticals, Inc (ENTA) is a NASDAQ Common Stock listed in , ,

970x250